 Market.webp)
Heparin-induced Thrombocytopenia Market size is expected to reach USD 63 Billion by the end of 2036, growing at a CAGR of 5% during the projected period i.e., between 2024-2036. In the year 2023, the industry size of heparin-induced thrombocytopenia was over USD 10 Billion. Heparin-induced thrombocytopenia may be a driving cause of horribleness and mortality in hospitalized patients, happening as an after-effect of life and limb-threatening thrombosis. In a least 5% of patients getting heparin, this condition is watched.There are signs of a diminish in the number of platelets by more than 50 % and encourage the arrangement of blood clots. Consequently, it is becoming profoundly vital to treat this condition, clearing the way for a have of treatment approaches.
Heparin is widely used in acute coronary syndromes, atrial fibrillation, venous thromboembolism, dialysis, peripheral occlusive disease, and during extracorporeal circulation which increases the risk of heparin-induced thrombocytopenia and drives heparin-induced thrombocytopenia market.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024 – 2036 |
|
CAGR |
~5% |
|
Base Year Market Size |
~USD 10 billion |
|
Forecast Year Market Size |
~USD 63 billion |
|
Regional Scope |
|
Drug Type (Lepirudin, Danaparoid, Argatroban)
Based on drug type, argatroban segment in the heparin-induced thrombocytopenia (HIT) market is set to hold the largest revenue share of 50% by the end of 2036. Due to the new product introductions in this segment, the argatroban treatment is expected to dominate the global market. For occurrence, in April 2023 Endo International plc's Par Sterile Products trade began dispatching argatroban infusion to healthcare providers by means of Premier's Chief ProRx private-label plan, a guarantor save for clinics and health frameworks. Argatroban is on the FDA's elementary drugs checklist and has experienced discontinuous save issues in the market.
End User (Hospitals, Diagnostic Centers, Specialized Clinics, Hospital Pharmacy, Homecare Setting, Mail Order Pharmacy)
In terms of end-user, the hospital segment is anticipated to hold 40% share of the global heparin-induced thrombocytopenia market by 2036. In order to provide special care for patients with HIT, hospitals and healthcare centers are well equipped. HIT is a complex condition that requires precise diagnosis, constant monitoring, and prompt treatment. In order to provide the level of care often required by HIT patients, these healthcare facilities have the necessary infrastructure, equipment, and experienced healthcare professionals.
Our in-depth analysis of the global market includes the following segments:
|
Drug Type |
|
|
Test Type |
|
|
End User |
|
North American Market Forecasts
The heparin-induced thrombocytopenia (HIT) Market in the North America region is anticipated to dominate the revenue, by registering growth of 35% by the end of 2036. Regional market growth is expected to be supported by an increased use of heparin in North America for the treatment of different disorders. Heparin is usually used for hemodialysis and the growing number of patients who are currently receiving dialysis will contribute to regional market growth. For instance, in February 2022, around 570,000 Americans receive dialysis, which indicates a notable heparin usage and its adverse drug reaction, Heparin-induced thrombocytopenia. In addition, regional market growth in the forecast period will be stimulated by recent product introductions on the market. For example, Gland Pharma Ltd., together with its associates MAIA Pharmaceuticals Inc. and Athenex Pharmaceutical Division, launched a ready to use formulation of Bivalirudin in the United States in June 2020. This was the first on-frozen ready-to-use bivalirudin 505b (2) NDA authorized by the U.S.
European Market Forecasts
The heparin-induced thrombocytopenia market in the Europe region is set to hold a substantial revenue share during the projected period. Continuous research and development in the field are leading to the introduction of novel therapies with enhanced efficacy and reduced side effects. This innovation is anticipated to attract new players and investments further propelling the heparin-induced thrombocytopenia market. expansion in the region. Furthermore, government initiatives and favorable reimbursement policies for effective HIT treatments can incentivize market growth and accessibility.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?